Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Generic medicines news


From To
Inactive Ingredients in Medications Cause Trouble for Some

Most approved medications have inactive ingredients that could cause problems for individuals with allergies or intolerances to those ingredients, researchers say. Those problems can add up when patients take more than one medication with troublesome ingredients.

14 March 2019
Medscape (requires free registration)
Trump’s Proposed Budget Undermines His H.I.V. Plan, Experts Say

Strategies abound to end the AIDS epidemic, but expense — mostly for drugs costing up to $50,000 a year — is the inevitable obstacle.

14 March 2019
The New York Times
Glimmers of hope: moving towards better HIV and TB treatment in eastern Europe

Eastern Europe continues to have one of the worst HIV epidemics in the world outside sub-Saharan Africa, with the worst linkage to care of any region in

07 February 2019
Gus Cairns
CHMP recommends for approval a generic version of atazanavir

At its January meeting, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended for approval a generic version of atazanavir – Atazanavir Krka for the treatment of HIV infection.

05 February 2019
Allowing Insurers to Dictate Therapies Harms People Living with HIV

A new proposed rule by the Trump Administration could give insurance companies the power to restrict access to medications that people living with HIV need. Under the proposal, insurance companies could also require “prior authorization” and/or “step therapy,” which would force patients to use and fail cheaper therapies before getting access to more effective ones.

29 January 2019
BETA blog
Cipla recalls 4,800 bottles of anti-HIV tablets from American market

Cipla is recalling 4,800 bottles of Nevirapine extended-release tablets used for the treatment of HIV from the American market.

30 December 2018
Business Today
Drug buyers' clubs aim to tackle HIV prevention 'crisis'

A new generation of drug buyers' clubs like those set up at the height of the AIDS epidemic is seeking to combat a "crisis" in preventing new HIV infections by providing access to cheap generics of a breakthrough prophylactic.

12 December 2018
Trump Wants to Restrict Access to HIV Meds for People on Medicare

In a move to cut Medicare costs, the proposed changes would also affect people with cancer, depression and schizophrenia.

29 November 2018
Gilead investors spooked by UnitedHealthcare push to cut HIV drug costs

Unveiled this week, UnitedHealthcare’s MyScriptRewards program will offer patients up to $500 in prepaid debit cards for medical expenses if they work with their doctors to choose lower-cost HIV drug regimens. The program is rolling out in HIV antivirals to start, with other specialty drug classes to follow.

05 November 2018
Generic PrEP bought online has correct amounts of emtricitabine and tenofovir

People buying generic PrEP (pre-exposure prophylaxis) online can be confident they are buying the real thing, according to research presented to the International Congress on Drug Therapy

28 October 2018
Michael Carter
← First12345...6Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.